Navigation Links
DSM and LibraGen Sign Agreement to Co-Develop Transaminases for Production of Chiral Amines
Date:9/15/2008

PARSIPPANY, N.J., VIENNA, Austria and TOULOUSE, France, Sept. 16 /PRNewswire/ -- DSM and LibraGen, a bacterial diversity-based process and discovery specialist, announced today that they have signed an agreement to co-develop new omega-transaminases for production of chiral amines. Under the terms of the partnership, LibraGen will use its proprietary enzyme discovery and development to identify new enzymes for efficient conversion of a large spectrum of ketons into optically pure R- and S-amines, a compound class highly relevant for fine chemicals and pharmaceuticals industries.

DSM will produce the enzymes at industrial scale using DSM's fermentation capabilities and proprietary expression platform, PluGbug(TM). LibraGen will sell the enzymes in kit form and both parties will use them for screening activities and the development of biocatalytic processes for third parties.

"This collaboration with LibraGen grows the number of available large-scale biocatalysts and will contribute to increasing competitiveness of the transaminase technology for production of chiral amines," said Oliver May, Competence Manager Biocatalysis at DSM Pharmaceutical Products. "In addition, by combining LibarGen's enzyme discovery and DSM's manufacturing capabilities the development timelines from enzyme discovery and screening to final product delivery to our customers will be significantly reduced," said Ronald Gebhard, R&D Director at DSM Pharmaceutical Products.

"We are delighted that we have signed this partnership with DSM," said Renaud Nalin, CEO of LibraGen. "It marks another step forward in the development of LibraGen's industrial biocatalysis capabilities. Customers of DSM and LibraGen will be able to use these new enzymes on a laboratory or industrial production scale to produce intermediates and APIs, thus making our response to market demands even more effective."

LibraGen expects this alliance to bring the company additional openings to provide its services to the fine chemicals, pharmaceutical and cosmetics customers, and to develop and optimize enzymatic synthesis processes for complex molecules.

Financial details of the collaboration were not disclosed.

About LibraGen

LibraGen, Toulouse, France, specializes in the development of innovative bioprocesses for molecule synthesis using biocatalysis for fine chemicals, cosmetics and pharmaceutical industries. One of LibraGen's key assets is its ability to look for high performance enzymes in bacteria populations that have not previously been explored and convert them into production tools. By combining the skills needed to go from R&D to pilot production, LibraGen is fulfilling a market need by giving its customers high performance and competitive synthesis solutions. Since the company was set up in 2001, LibraGen's reactivity and innovation has resulted in its becoming the exclusive producer of active enzymes for a number of third parties. More information: http://www.libragen.com

About DSM Pharmaceutical Products

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), fermentation, mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: http://www.dsmpharmaceuticals.com

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: http://www.dsm.com.

Forward-looking statements

Any forward-looking statements contained in this press release that involve inherent risks and uncertainties are based on current expectations, estimates and projections of the management of DSM and information currently available. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update any statements contained in this press release.

For further information please contact:

DSM Pharmaceutical Products

Guy Tiene

Director, Marketing & Communications

Tel: +1-973-257-8160

guy.tiene@dsm.com

DSM Pharmaceutical Products

Oliver May

Competence Manager Biocatalysis

Tel: +31 (46) 4760551

Oliver.May@DSM.com

LibraGen

Renaud Nalin

Chief Executive Officer

Tel: +33 562 193 290

nalin@libragen.com

LibraGen

Fabrice Lefevre

Chief Scientific Officer

Tel: +33 562 193 297

f.lefevre@libragen.com


'/>"/>
SOURCE DSM Pharmaceutical Products
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Lilly and Glenmark Pharmaceuticals Announce License Agreement
8. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
9. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
10. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
11. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... announced the launch of a Phase 2 clinical study ... hearing in patients undergoing cochlear implantation (CI) surgery. This ... patients in Germany and ... the middle ear at the time of surgery. "Despite ...
(Date:4/26/2016)... CHICAGO , April 26, 2016 Hill-Rom Holdings, ... to a management presentation at the Deutsche Bank 41 st ... at 2:50 p.m. EDT. You are invited to ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas ... one hour after conclusion of the live event and accessible ...
(Date:4/26/2016)... , April 27, 2016 Research ... "Global Molecular Diagnostics Market 2016-2020" report to their ... , ,The global molecular diagnostics market is projected to ... 2016-2020. Molecular diagnostics is a technique that ... the molecular level to detect changes in biochemical pathways. ...
Breaking Medicine Technology:
(Date:5/1/2016)... ... ... 2 is a set of versatile and smooth logo reveals built exclusively for Final ... a unique logo reveal in just a matter of minutes. Custom settings give the user ... add a uniquely animated logo to any photos or videos. , ProBrand Reveal comes packaged ...
(Date:4/30/2016)... ... 30, 2016 , ... Create an abstract shape animation with ... manipulate three-dimensional shapes with ease all within Apple Motion . Users have ... texture animation, opacity texture animation, overall shape texture displacement, twist, camera controls, and ...
(Date:4/30/2016)... ... April 30, 2016 , ... Dr. Trevor Gardner, President ... today signed a multifaceted agreement which will allow for the research and development ... of Natural and Applied Sciences, Allied Health and Nursing will work together to ...
(Date:4/29/2016)... ... April 30, 2016 , ... World ... the Pick Up Springboard, an automotive invention that improves the storage features of ... worth $162 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial Healthcare System ... Medical Education (ACGME) that it has received accreditation for its residency program on ... residency programs that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This ...
Breaking Medicine News(10 mins):